This section of our website contains archival information which should not be considered current and may no longer be accurate.



Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
August 4, 2010

Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
June 28, 2010

Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
June 28, 2010

Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
June 25, 2010

Single Short Course of Tolerx’s Otelixizumab Provides Prolonged Preservation of Beta Cell Function
March 16, 2010

Tolerx Completes Enrollment in DEFEND-1, a Phase 3 Type 1 Diabetes Study with Otelixizumab
January 7, 2010

Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress
October 21, 2009

Tolerx Announces Amendment to Phase 3 DEFEND Protocol
August 11, 2009

Tolerx Presents Data at 69TH Scientific Sessions of The American Diabetes Association
June 8, 2009

Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe
March 10, 2009

Laureate Announces Manufacturing Agreement with Tolerx
October 21, 2008

Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
August 6, 2008

Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
August 5, 2008

Tolerx Named as One of the "Fierce 15" Biotech Companies of 2008
June 24, 2008

Tolerx Announces Data Presentations at American Diabetes Association 68th Scientific Sessions 2008
June 3, 2008

Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
April 9, 2008

Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
January 15, 2008

GlaxoSmithKline And Tolerx Form Worldwide Collaboration For Development And Commercialization Of Novel Medication
October 23, 2007

Tolerx, Inc. Raises $35.6 Million to Advance TRX4 in Type 1 Diabetes
August 16, 2006

Tolerx Receives Orphan Drug Designation from FDA for TRX4 for the Treatment of New-Onset Type 1 Diabetes
February 14, 2006

Tolerx Initiates Three Clinical Trials in Autoimmune Indications
December 7, 2005

Tolerx, Inc. Announces Manufacturing and Commercial Supply Agreement with Abbott for TRX4
November 29, 2005

Positive Data from Type 1 Diabetes Study of Tolerx's TRX4 Published in the New England Journal of Medicine
June 23, 2005

Tolerx, Inc. Acquires Assets for Lead Product, TRX4
April 4, 2005

Tolerx, Inc. Completes $31 Million Series D Financing
March 29, 2005

Tolerx Initiates Clinical Trial of TRX4 for Psoriasis
August 2, 2004

Tolerx Withdraws Registration Statement
July 26, 2004

Tolerx, Inc. Announces the Appointment of Ian F. Smith to its Board of Directors
April 5, 2004

Tolerx Delays Initial Public Offering to Complete Analysis of Preclinical Data
November 19, 2003

Tolerx Files for Initial Public Offering
August 26, 2003

Tolerx Announces the Appointment of James E. Niedel to its Board of Directors
January 8, 2003

Tolerx Signs TRX1 Collaboration Agreement With Genentech
January 3, 2003

Tolerx Completes $35 Million Series C Financing
January 3, 2003

Tolerx Announces Appointment of Louis Vaickus, M.D. as Vice President and Head of Clinical Development and Medical Affairs
August 21, 2002

Laureate Pharma L.P. and Tolerx, Inc. Announce Antibody Manufacturing Services Agreement
July 15, 2002

Tolerx Completes $17 Million Series B Financing
October 23, 2001